ABSTRACT We previously published on the design and synthesis of novel, potent and selective PPARα antagonists suitable for either i.p. or oral in vivo administration for the potential treatment of cancer. Described herein is SAR for a subsequent program, where we set out to identify selective and potent PPARα/δ dual antagonist molecules. Emerging literature indicates that bothRead More
Dog Peroxisome Proliferator-Activated Receptor Delta (dPPARδ/dPPARβ; nr1c2)
Dog Peroxisome Proliferator-Activated Receptor Delta (dPPARδ/dPPARβ; nr1c2) Product Family Product Number Product Description Technical Manual D0012 dPPARδ (nr1c2) D00121-32 Dog PPARδ Reporter Assay System, 3 x 32 assays in 96-well format D00121 Dog PPARδ Reporter Assay System, 1 x 96-well format assays
Cyn Monkey Peroxisome Proliferator-Activated Receptor Delta (cPPARδ/cPPARβ; nr1c2)
Cyn Monkey Peroxisome Proliferator-Activated Receptor Delta (cPPARδ/cPPARβ; nr1c2) Product Family Product Number Product Description Technical Manual C0012 cPPARδ (nr1c2) C00121-32 Cyn Monkey PPARδ Reporter Assay System, 3 x 32 assays in 96-well format C00121 Cyn Monkey PPARδ Reporter Assay System, 1 x 96-well format assays
Identification and Molecular Characterization of Peroxisome Proliferator-Activated Receptor δ as a Novel Target for Covalent Modification by 15-Deoxy-Δ12,14-prostaglandin J2
ABSTRACT PPARδ belongs to the peroxisome proliferator-activated receptor (PPAR) family of nuclear receptors. Upon activation by an agonist, PPARδ controls a variety of physiological processes via regulation of its target genes. 15-Deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) is a cyclopentenone prostaglandin that features an electrophilic, α,β-unsaturated ketone (an enone) in the cyclopentenone ring. Many of 15d-PGJ2’s biological effects resultRead More
Comparative Evaluation of Gemcabene and Peroxisome Proliferator–Activated Receptor Ligands in Transcriptional Assays of Peroxisome Proliferator–Activated Receptors: Implication for the Treatment of Hyperlipidemia and Cardiovascular Disease
ABSTRACT Gemcabene, a late-stage clinical candidate, has shown efficacy for LDL-C, non-HDL cholesterol, apoB, triglycerides, and hsCRP reduction, all risk factors for cardiovascular disease. In rodents, gemcabene showed changes in targets, including apoC-III, apoA-I, peroxisomal enzymes, considered regulated through peroxisome proliferator–activated receptor (PPAR) gene activation, suggesting a PPAR-mediated mechanism of action for the observed hypolipidemic effects observedRead More